Form 4: BridgeBio Pharma Director Ali J. Satvat Receives Significant Equity Grants

BridgeBio Pharma, Inc. Director Ali J. Satvat was granted 6,589 Restricted Stock Units and options to purchase 8,425 shares of common stock, aligning his interests with shareholders.

Summary

• Ali J. Satvat, a Director and 10% Owner of BridgeBio Pharma, Inc. (BBIO), reported an acquisition of equity securities on June 20, 2025.
• The acquisition included a grant of 6,589 Restricted Stock Units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, with a reported acquisition price of $0.
• One-third of these RSUs will vest each year after June 20, 2025, leading to full vesting on June 20, 2028, contingent on Mr. Satvat's continued service on the board.
• Following this transaction, Mr. Satvat beneficially owns 165,993 shares of Common Stock directly.
• Additionally, Mr. Satvat was granted stock options to acquire 8,425 shares of Common Stock, with an exercise price of $41.73 per share and a reported acquisition price of $0.
• One-third of the shares underlying these stock options will vest each year after June 20, 2025, with full vesting by June 20, 2028, also subject to continued board service.
• These stock options have an expiration date of June 19, 2035.
• Following this transaction, Mr. Satvat beneficially owns 8,425 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine filing, the grant of equity to a director aligns their interests with shareholders, which is generally viewed favorably as it incentivizes long-term performance and commitment. There are no negative implications from this specific transaction.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns management's and the board's interests with those of the shareholders, incentivizing long-term performance and value creation.
• The equity grants are part of a structured incentive plan, indicating a commitment to retaining key personnel and rewarding their contributions.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon Mr. Satvat's continued service on BridgeBio Pharma, Inc.'s board of directors, meaning the benefits are not guaranteed if his service ceases before the vesting dates.

Future Outlook

The equity grants, with their multi-year vesting schedule extending to June 20, 2028, indicate an expectation of continued service from Director Ali J. Satvat and a long-term incentive structure for his contributions to the company.

Industry Context

The granting of Restricted Stock Units and stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of non-cash compensation designed to align the interests of board members with long-term shareholder value creation. This practice is widely adopted across publicly traded companies to incentivize performance and retention.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a component of director compensation is a common and accepted practice across the biotechnology and broader corporate landscape, consistent with compensation strategies at companies like Amgen Inc., Gilead Sciences, Inc., and Biogen Inc., which frequently utilize equity-based incentives for their board members.
• The vesting schedule of one-third per year over three years is a typical structure for such grants, balancing immediate incentive with long-term retention, similar to practices observed in many S&P 500 companies.
• The grant price of $0 for RSUs and options is standard for compensatory grants, reflecting their nature as incentives rather than purchases at market value.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Ali J. Satvat, a director and 10% owner, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's financial interests with those of the shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: While not directly impacting employees, the incentive plan under which these grants were made may also apply to other key personnel, fostering a performance-driven culture.

Next Steps

• Continued service of Ali J. Satvat on the BridgeBio Pharma, Inc. board of directors.
• Annual vesting of the granted Restricted Stock Units and stock options on June 20, 2026, June 20, 2027, and June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Executive Compensation, Corporate Governance, Biotechnology, Pharmaceuticals